Values First Advisors’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-2,673
Closed -$91K 294
2024
Q3
$91K Buy
+2,673
New +$75.2K 0.05% 188
2023
Q2
Sell
-3,587
Closed -$80K 333
2023
Q1
$80K Buy
+3,587
New +$86.7K 0.05% 171
2022
Q2
Sell
-15,899
Closed -$438K 173
2022
Q1
$438K Buy
15,899
+4,775
+43% +$137K 0.28% 102
2021
Q4
$458K Sell
11,124
-611
-5% -$27K 0.27% 102
2021
Q3
$545K Buy
11,735
+2,850
+32% +$124K 0.35% 89
2021
Q2
$355K Buy
8,885
+2,905
+49% +$124K 0.24% 119
2021
Q1
$321K Sell
5,980
-1,950
-25% -$112K 0.24% 120
2020
Q4
$388K Sell
7,930
-2,571
-24% -$119K 0.31% 108
2020
Q3
$341K Sell
10,501
-46
-0.4% -$1.46K 0.31% 106
2020
Q2
$273K Buy
+10,547
New +$263K 0.27% 107

Other funds holding VCYT

Values First Advisors's VCYT Position: Q4 2024 in Review

Values First Advisors sold out of Veracyte (VCYT) in Q4 2024, closing a stake of 2,673 shares — an estimated $91K sold.

Values First Advisors first reported a position in VCYT in Q2 2020 and held it in 10 quarters. The position peaked at $545K in Q3 2021. 318 funds tracked by Wall St. Rank hold VCYT as of Q4 2024.

  • Values First Advisors reported no remaining Veracyte position as of Q4 2024 after selling out during the quarter.
  • Values First Advisors sold 2,673 Veracyte shares in Q4 2024, an estimated $91K.
  • Values First Advisors first reported a position in Veracyte in Q2 2020 and held it in 10 quarters.
  • Values First Advisors's Veracyte position peaked at $545K in Q3 2021.
  • 318 funds tracked by Wall St. Rank held Veracyte as of Q4 2024.

Based on Values First Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.